logo
Plus   Neg
Share
Email

Vulcan Materials Expects Double-digit Growth In FY20 Earnings - Quick Facts

While reporting its financial results for the fourth quarter on Tuesday, Vulcan Materials Co. (VMC) provided its financial outlook for fiscal 2020, saying it expects double-digit growth in earnings for the year.

For fiscal 2020, Vulcan Materials projects earnings from continuing operations of $5.20 to $5.80 per share, adjusted EBITDA of $1.385 billion to $1.485 billion, and aggregates shipments growth of 2 percent to 4 percent. The company reported adjusted earnings from continuing operations of $4.70 per share for fiscal 2019.

On average, analysts polled by Thomson Reuters expect the company to earnings of $5.72 per share for the year on revenues of $5.28 billion. Analysts' estimates typically exclude special items.

"Looking ahead, demand in our markets will continue to benefit from higher levels of highway funding and continued growth in residential and nonresidential markets. This visibility into demand growth has already set the stage for solid price improvement in 2020," said Tom Hill, Chairman and Chief Executive Officer of Vulcan Materials.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Samsung Electronics Co Ltd (SMSN.L, SSNNF.OB, SSNLF.OB) expects that its first-quarter operating profit will increase about 2.73 percent from last year, sales will also increase 4.98 percent. JPMorgan Chase CEO Jamie Dimon said it expects the bank's earnings to be "down meaningfully" in 2020 due to the disruptions created by coronavirus pandemic. He also noted that the U.S. was not adequately prepared for the pandemic. In his annual letter to the company's shareholders, Dimon said that the bank's board may consider suspending the dividend in an extremely adverse scenario. The U.S. Food and Drug Administration launched a national effort to facilitate the development of blood-related therapies to combat the ongoing coronavirus (COVID-19) pandemic. The FDA is focused on two investigational therapies derived from human blood called convalescent plasma and hyperimmune globulin, which are antibody-rich blood products made from blood donated by people who have recovered.
Follow RTT
>